Clinical Trial Update: COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2 [Phase 2]

View source ↗

Summary

Phase 2 trial in COPD and bronchiectasis patients at risk of viral infections (including SARS-CoV-2) was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis
• Chronic Obstructive Pulmonary Disease

Snippet

Sponsor: Thirty Respiratory Limited | Conditions: COPD, Bronchiectasis | Phase 2 | Status: TERMINATED | Results posted: 2025-01-31